PMID- 11697543
OWN - NLM
STAT- MEDLINE
DCOM- 20020402
LR  - 20190710
IS  - 0022-3573 (Print)
IS  - 0022-3573 (Linking)
VI  - 53
IP  - 10
DP  - 2001 Oct
TI  - Arginine vasopressin release in response to the administration of 
      3,4-methylenedioxymethamphetamine ("ecstasy"): is metabolism a contributory 
      factor?
PG  - 1357-63
AB  - The aim of this investigation was to examine the effect of 
      3,4-methylenedioxymethamphetamine (MDMA) administration on arginine vasopressin 
      (AVP) release. (R,S)-MDMA (40 mg) was administered to eight normally hydrated 
      healthy male volunteers (22-32 years) and blood samples were collected up to 24 
      h. Plasma was assayed for AVP and cortisol by radioimmunoassays, and for MDMA and 
      the N-demethylated metabolite, MDA, by gas chromatography-mass spectrometry. 
      Sodium concentrations and osmolality were also determined. Plasma AVP increased 
      in all subjects after MDMA administration and a significant negative correlation 
      was observed between concentrations of AVP and both single and total enantiomer 
      MDMA at 1 h (r < -0.91, P < 0.01). This had disappeared by 2 h (P > 0.7). 
      Compared with basal values, no significant change was observed for osmolality or 
      cortisol at 1 h after drug administration. In conclusion, plasma AVP 
      concentrations increase after MDMA administration, but the increase is not part 
      of a generalized stress response since cortisol did not increase concurrently. A 
      significant negative correlation between plasma MDMA and AVP was observed soon 
      after administration. The possibility that a pharmacological effect of MDMA is 
      primarily mediated via one or more metabolites, rather than by the parent drug, 
      should be considered.
FAU - Forsling, M
AU  - Forsling M
AD  - Neuroendocrine Laboratories, New Hunts House, King's College London, Guy's 
      Hospital, UK.
FAU - Fallon, J K
AU  - Fallon JK
FAU - Kicman, A T
AU  - Kicman AT
FAU - Hutt, A J
AU  - Hutt AJ
FAU - Cowan, D A
AU  - Cowan DA
FAU - Henry, J A
AU  - Henry JA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Hallucinogens)
RN  - 113-79-1 (Arginine Vasopressin)
RN  - 9NEZ333N27 (Sodium)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Adult
MH  - Arginine Vasopressin/*metabolism
MH  - Biotransformation
MH  - Hallucinogens/blood/pharmacokinetics/*pharmacology
MH  - Humans
MH  - Hydrocortisone/blood
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/blood/pharmacokinetics/*pharmacology
MH  - Osmolar Concentration
MH  - Sodium/blood
MH  - Stereoisomerism
EDAT- 2001/11/08 10:00
MHDA- 2002/04/03 10:01
CRDT- 2001/11/08 10:00
PHST- 2001/11/08 10:00 [pubmed]
PHST- 2002/04/03 10:01 [medline]
PHST- 2001/11/08 10:00 [entrez]
AID - 10.1211/0022357011777855 [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 2001 Oct;53(10):1357-63. doi: 10.1211/0022357011777855.